Literature DB >> 28150095

Risk of ventricular tachyarrhythmias following improvement of left ventricular ejection fraction in patients with implantable cardiac defibrillators implanted for primary prevention of sudden cardiac death.

Jayasree Pillarisetti1,2, Rakesh Gopinathannair3, Matthew J Haney3, Bassem Abazid3, Wasiq Rawasia3, Madhu Yeruva Reddy4,5, Niveditha Adabala4,5, Sudharani Bommana4,5, Martin Emert4,5, Dhanunjaya Lakkireddy4,5.   

Abstract

PURPOSE: In patients who undergo implantable cardiac defibrillator (ICD) implantation for primary prevention of sudden cardiac death (SCD), data is unclear whether their ICD generator needs to be replaced at end of life if their left ventricular ejection fraction (EF) improves. Despite improvement in EF, the underlying scar may represent a potential substrate for ventricular arrhythmias.
METHODS: Data on 280 patients who underwent ICD implantation for primary prevention of SCD was obtained from two centers. Patients were followed for any improvement in EF to ≥35%. All arrhythmic events during follow-up, including appropriate and inappropriate shocks/ATP, were recorded.
RESULTS: Thirty percent (n = 86/280) of patients improved their EF to >35% of which 41% (n = 37) underwent a generator change by the study ending period with the rest not yet at ERI. Mean baseline EF in patients with and without target EF improvement was 26 ± 7 and 23 ± 7% (p = 0.2). After excluding patients whose arrhythmic events data were unavailable, the final sample consisted of 62 patients in the EF improvement group and 156 patients in the group without EF improvement. In the group with EF improvement, appropriate events (shock + ATP) were noted in 19% of patients (n = 12/62) and inappropriate shocks and ATP in 6% of (n = 4/62) patients after their EF improved to >35%. Four patients received appropriate therapies when their EF was low prior to improvement. In contrast, in patients who had no improvement in EF, 27% (n = 43/156) received an appropriate therapy (p = 0.6) while 11% (n = 18/156) (p = 0.2) received inappropriate shocks and ATP. All-cause mortality was higher in patients without subsequent improvement in EF versus those with EF improvement (31 vs. 15% (p = .005).
CONCLUSIONS: There was no significant difference in the number of appropriate therapies received by each group. Patients continue to be at high risk for sudden cardiac death despite improvement in EF.

Entities:  

Keywords:  Generator change; Primary prevention; Sudden cardiac death

Mesh:

Year:  2017        PMID: 28150095     DOI: 10.1007/s10840-017-0222-1

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  25 in total

1.  Lessons from a population: the limitations of left ventricular ejection fraction as the major determinant for primary prevention implantable cardioverter-defibrillators.

Authors:  William J Groh
Journal:  J Am Coll Cardiol       Date:  2006-02-23       Impact factor: 24.094

2.  ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities.

Authors:  Andrew E Epstein; John P Dimarco; Kenneth A Ellenbogen; N A Mark Estes; Roger A Freedman; Leonard S Gettes; A Marc Gillinov; Gabriel Gregoratos; Stephen C Hammill; David L Hayes; Mark A Hlatky; L Kristin Newby; Richard L Page; Mark H Schoenfeld; Michael J Silka; Lynne Warner Stevenson; Michael O Sweeney
Journal:  Heart Rhythm       Date:  2008-05-21       Impact factor: 6.343

3.  Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.

Authors:  Arthur J Moss; Wojciech Zareba; W Jackson Hall; Helmut Klein; David J Wilber; David S Cannom; James P Daubert; Steven L Higgins; Mary W Brown; Mark L Andrews
Journal:  N Engl J Med       Date:  2002-03-19       Impact factor: 91.245

4.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.

Authors:  Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

5.  16-year trends in the infection burden for pacemakers and implantable cardioverter-defibrillators in the United States 1993 to 2008.

Authors:  Arnold J Greenspon; Jasmine D Patel; Edmund Lau; Jorge A Ochoa; Daniel R Frisch; Reginald T Ho; Behzad B Pavri; Steven M Kurtz
Journal:  J Am Coll Cardiol       Date:  2011-08-30       Impact factor: 24.094

6.  A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.

Authors: 
Journal:  N Engl J Med       Date:  1997-11-27       Impact factor: 91.245

7.  Marked improvement in left ventricular ejection fraction during long-term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance.

Authors:  Marco Metra; Savina Nodari; Giovanni Parrinello; Raffaele Giubbini; Carlo Manca; Livio Dei Cas
Journal:  Am Heart J       Date:  2003-02       Impact factor: 4.749

8.  Randomized study of implantable defibrillator as first-choice therapy versus conventional strategy in postinfarct sudden death survivors.

Authors:  E F Wever; R N Hauer; F L van Capelle; J G Tijssen; H J Crijns; A Algra; A C Wiesfeld; P F Bakker; E O Robles de Medina
Journal:  Circulation       Date:  1995-04-15       Impact factor: 29.690

9.  Left ventricular function improvement after prophylactic implantable cardioverter-defibrillator implantation in patients with non-ischaemic dilated cardiomyopathy.

Authors:  Wolfram Grimm; Nina Timmesfeld; Elena Efimova
Journal:  Europace       Date:  2013-05-02       Impact factor: 5.214

10.  Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study.

Authors:  Alfred E Buxton; Kerry L Lee; Gail E Hafley; Luis A Pires; John D Fisher; Michael R Gold; Mark E Josephson; Michael H Lehmann; Eric N Prystowsky
Journal:  J Am Coll Cardiol       Date:  2007-09-04       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.